Strategic Partnerships Daisy Genomics has active collaboration momentum with Oak Ridge National Laboratory, University of Tennessee, New Day Diagnostics, and ETHIA, indicating a ready-made entry path for joint development initiatives, pilot programs, or sponsored research services in cancer diagnostics and epigenetic sequencing.

Early Stage Upsell As an early-stage biotech with a focus on proprietary optical sequencing, there is potential to offer specialized cloud-based data processing, Raman spectroscopy tooling, and bioinformatics support services to streamline their platform development and reduce time-to-insight.

Epigenetic Focus Daisy’s emphasis on next-generation epigenetic sequencing and liquid biopsy tools for colorectal cancer presents opportunities to position complementary reagents, assay development services, and regulatory/compliance advisory packages tailored to precision oncology workflows.

Technology Enablement Their tech stack and cloud orientation (AWS, Cloudflare, Microsoft 365) suggest value in scalable cloud infrastructure optimization, data security enhancements, and managed services that support rapid iteration of optical sequencing experiments.

Funding & Growth Signals With reported revenue and $8.5M in funding, plus multiple press-driven partnerships, there is room for strategic collaborations, pilot funding programs, and sponsored research engagements to accelerate platform maturation and generate joint go-to-market opportunities.